Episode Details

Hospitalisation among vaccine breakthrough COVID-19 infections https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00558-2/fulltext Robust vaccine efficacies at preventing severe symptomatic disease Breakthrough SARS-CoV-2 infections in fully vaccinated https://covid.joinzoe.com/post/worryingly-close-to-100-000-new-cases-a-day Impact of vaccination on admission to hospital Patients with confirmed SARS-CoV-2 infection Yale New Haven Health System, Connecticut Between March 23 and July 1, 2021 Patients were considered fully vaccinated 14 days after second dose 969 patients were admitted PCR positive 172 (18%) of 969 patients had received at least one vaccine dose 103 had received a partial vaccine course 15 had received a complete course 54 were fully vaccinated Among the 54 25 (46%) patients were asymptomatic 4 (7%) had mild disease 11 (20%) had moderate disease 14 (26%) had severe or critical illness 4 (7%) required ICU 1 required ventilation 3 died Among those with severe or critical illness Median age 80·5 years Pre-existing comorbidities in the 14 patients with severe or critical illness Body–mass index more than 25 kg/m² (n=9) Cardiovascular disease (n=12) Lung disease (n=7) Malignancy (n=4) Type 2 diabetes (n=7) Immunosuppressive agent (n=4) Difference between vaccines 13 of 14 patients had received BNT162b2, Pfizer 1 of the 14 had received mRNA-1273, Moderna 0 of the 14 had received Ad.26. COV2.S, J and J May 17, 2021, vaccine doses in Connecticut Pfizer, 1, 358, 175 Moderna, 1, 044, 420 J and J, 267, 000

Learn more about your ad choices. Visit megaphone.fm/adchoices